Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New US Indication May Help Finally Get Keryx' Auryxia Off The Ground

Executive Summary

Company plans to use the same sales force and broad insurance coverage for oral iron product in new use for CKD patients with iron deficiency anemia not on dialysis, as for the first approved use in dialysis patients, so it will "hit the ground running."

You may also be interested in...

Akebia And Keryx To Merge, Establishing Critical Mass In Renal Disease

Planned all-stock transaction would bring together Akebia’s R&D organization and Keryx’s commercial apparatus for Auryxia. That drug and Akebia’s Phase III vadadustat would create a complementary franchise, CEO Butler asserts.

Keryx Looks To Label Expansion To Drive Auryxia

Keryx plans to expand Aurexia’s label to treat iron deficiency in pre-dialysis patients while searching for additional nephrology assets during 2017.

Phase III Data Back Keryx's Plan To Expand Auryxia Market

Keryx Biopharmaceuticals Inc. had a rough first year of sales for its oral, iron-based phosphate binder Auryxia (ferric citrate), but the company and it investors have high hopes that new Phase III data will support approval for a second indication that could double the drug's market.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts